IntraBio Announces Clinical Results of Dementia Treatment – Press Releases

OXFORD, UK / ACCESSWIRE / 28 November 2018 / IntraBio Inc., a developmental biopharmaceutical company developing new therapies for common and rare ("orphan") neurodegenerative diseases, has announced the results of its series of pilot compounds (IB1000) for the treatment of dementia, including Positive clinical results from studies for compbadionate use in patients with Lewy body dementia and frontotemporal dementia, as well as preclinical studies on the disease of dementia. Alzheimer.

Recent studies on the use of compbadion with IB1000 in patients with Lewy body dementia and frontotemporal dementia have shown a significant improvement in quality of life, cognition, mobility, speech and a disease modifying effect. Clinical examinations and the badysis of walking revealed a marked improvement in walking and balance, and neuropsychological tests revealed a measurable improvement in psychomotor function, alertness and alertness. ;Warning.

Additional pre-clinic in vivo studies (in Npc1^{– / –} mouse model) that studies the effect of IB1000 on the pathology of Alzheimer's disease strongly corroborated the effect of treatment, demonstrating a statistically significant improvement in two critical biomarkers: Conjugated to protein 1A / 1B-light chain 3 -phosphatidylethanolamine (LC3-II) reduced by 68% and the C-terminal protein fragments of the amyloid precursor protein (APP-CTF) were reduced by 28%.

The discovery of symptomatic and neuroprotective properties and the potential for modifying IB1000 disease could be a breakthrough for patients with a wide range of neurodegenerative diseases, including dementia.

"Although the size of the original sample is reduced, having a drug with an excellent long-term safety profile and showing promising effects on these incurable diseases is a development." very interesting and important, "commented Professor Antony Galione FRS FMedSci, statutory professor of pharmacology. , Oxford University and founding scientist of IntraBio.

Alzheimer's disease, Lewy body dementia, and frontotemporal dementia together account for approximately 85-90% of dementia cases, affecting more than 50 million people worldwide, and their prevalence is expected to increase over the next decade. the next decades and reach more than 100 million people in 2050. These are progressive neurological disorders in which abnormal protein deposits accumulate in areas of the brain that regulate cognition, behavior and behavior. movement. As a result, they exhibit a wide range of cognitive, behavioral, and physical symptoms, including memory, thinking, sleep, motor function, and behavioral change.

IntraBio, with its collaborators, evaluated the effect of IB1000 in compbadionate use studies in more than 175 patients, thus constituting the scientific basis for the IB1000 to be further investigated for the treatment of 18 indications, including diseases. neurodegenerative disorders and lysosomal storage disorders. Future possibilities for developing the IB1000 series in other indications include parkinsonism, restless leg syndrome (SJS), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), all of which have high unmet medical needs.

IntraBio is currently preparing multinational clinical trials with its major active ingredient (IB1001) for the treatment of Niemann-Pick type C (CML), gangliosidosis GM2 (Tay-Sachs and Sandhoff disease) and certain hereditary cerebellar ataxias . (CALIFORNIA).

About Lewy Body Dementia

Lewy body dementia (LBD) is a progressive brain disorder in which Lewy bodies (abnormal deposits of a protein called alpha-synuclein) accumulate in areas of the brain that regulate behavior, cognition and movements. Gradually debilitating, the LBD can present a range of generally fluctuating symptoms, including problems of thinking, memory, movement, sleep and / or behavioral change. LBD also affects autonomic body functions, such as blood pressure control, temperature regulation, and bladder and bowel function.

About fronto-temporal dementia

Frontotemporal dementia (FTD) refers to a group of disorders caused by a progressive loss of nerve cells mainly in the frontal lobes of the brain and its temporal lobes. The FTD can have a significant impact on the patient's daily life by changing personalities and behavior and severely impairing language, speech, writing and comprehension skills. FTD once called Pick's disease, according to Arnold Pick, M.D., a physician who, in 1892, first described a patient with distinct symptoms affecting language. Some doctors still use the term "Pick's disease".

About IntraBio

IntraBio Inc. is a biopharmaceutical company with a pipeline of late-stage drugs, including new treatments for common and rare neurodegenerative diseases. The IntraBio platform is the result of decades of research and investment in the best universities and institutions around the world. Its clinical programs rely on the lysosomal function and intracellular calcium signaling skills of its founding scientists from Oxford University and the University of Munich.

The IntraBio management team and consultants have extensive commercial experience and successful experience with drug development in the United States and Europe. Together, the IntraBio team translates innovative scientific research in the areas of lysosomal biology, autophagy and neurology into innovative drugs for a wide range of genetic and neurodegenerative diseases to help address the world's challenges. Significantly improve the lives of patients and their families.

IntraBio Inc. is an American company with principal laboratories and offices in Oxford, UK.

For more information, please contact:

Cbad Fields
[email protected]
www.intrabio.com

SOURCE: IntraBio Inc.

See the source version on accesswire.com:
https://www.accesswire.com/529134/IntraBio-Announces-Clinical-Results-for-Treatment-of-Dementia